Clexio Biosciences
Omri Erez is an experienced professional in the field of drug discovery and preclinical development, currently serving as the Head of Preclinical Development at Clexio Biosciences since August 2023. Previously, Omri was the VP of Drug Discovery at Protai, where responsibilities included leading biological R&D focused on target and biomarker discovery using CRISPR and proteomics, as well as small-molecule drug discovery. Prior to that, Omri held various leadership roles at Metabomed Ltd. as SVP and VP of Biology, contributing to cancer metabolism drug discovery. Omri began the career as Head of Discovery at Proteologics, emphasizing the development of novel small molecule inhibitors. Educational qualifications include a PhD and MSc in Molecular Genetics from the Weizmann Institute of Science, and a BSc in Biology from The Hebrew University of Jerusalem.
This person is not in any teams
This person is not in any offices
Clexio Biosciences
Clexio Biosciences is a CNS-first clinical-stage pharmaceutical company. Our therapies are designed to address patients’ unmet needs through scientifically based integration of drugs with innovative technologies. Clexio’s growing pipeline is focused on the development of safe and effective treatments with rapid onset of action for a wide range of neurological and psychiatric conditions, including Major Depressive Disorder, Parkinson’s Disease, Pain and other conditions involving impairment of the neurological system. Patients, and what they are living with, are at the center of everything we do. Our passion is to find ways to help patients regain a sense of balance, health and a life worth living. Clexio’s team is comprised of a multi-disciplinary team with vast experience in drug development. We see our team and our partners as the key ingredients to our success. Join our vision to make lives of millions of patients worth living again.